Qiagen (NYSE:QGEN) Issues Q1 Earnings Guidance

Qiagen (NYSE:QGEN - Get Free Report) updated its first quarter earnings guidance on Monday. The company provided earnings per share guidance of at least $0.55 for the period, compared to the consensus earnings per share estimate of $0.49. The company issued revenue guidance of ~$483 million, compared to the consensus revenue estimate of $464.42 million. Qiagen also updated its FY 2025 guidance to 2.350- EPS.

Qiagen Price Performance

Shares of Qiagen stock traded up $1.93 on Friday, reaching $41.98. 1,723,550 shares of the stock were exchanged, compared to its average volume of 1,119,244. The firm's 50 day moving average is $39.75 and its 200-day moving average is $41.81. The firm has a market cap of $9.33 billion, a PE ratio of 116.88, a P/E/G ratio of 2.39 and a beta of 0.62. Qiagen has a one year low of $37.63 and a one year high of $49.30. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. As a group, analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on QGEN. UBS Group cut their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Robert W. Baird downgraded shares of Qiagen from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $52.00 to $42.00 in a report on Wednesday, February 19th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $46.67 target price (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Finally, Redburn Atlantic lowered Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Eight equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Qiagen has an average rating of "Hold" and a consensus target price of $47.71.

Remove Ads

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.